BC Extra | Oct 31, 2019
Company News

Dicerna’s latest deal lands $200M, Roche as partner in HBV

A year after completing a pair of deals in the span of a week, Dicerna has partnered a Phase I HBV asset with Roche in an RNAi deal that brings in $200 million up front....
BC Extra | Oct 4, 2019
Clinical News

Arbutus scuttles lead HBV capsid inhibitor program

Arbutus scrapped plans to start a combination trial next year due to the emergence of a safety signal in two healthy volunteers in a Phase I study of AB-506, an oral capsid inhibitor expected to...
Items per page:
1 - 2 of 2